Mechanism of new antipsychotic medications: Occupancy is not just antagonism

Gerhard Gründer, Arvid Carlsson, Dean Foster Wong

Research output: Contribution to journalArticle

Abstract

Antagonism of D2-like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80% (striatal) D2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D 2-like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is aripiprazole's weak partial agonism at D2-like dopamine receptors. This particular pharmacologic feature characterizes a new class of atypical antipsychotics that does not match the original concept of a therapeutic occupancy window for antagonist antipsychotics. When not involving pure antagonists, it implies a need to adjust the expected receptor occupancy (measured using positron emission tomography) for the therapeutic window.

Original languageEnglish (US)
Pages (from-to)974-977
Number of pages4
JournalArchives of General Psychiatry
Volume60
Issue number10
DOIs
StatePublished - Oct 1 2003

Fingerprint

Antipsychotic Agents
Corpus Striatum
Dopamine D2 Receptors
Dopamine Antagonists
Psychotropic Drugs
Incidence
Dopamine Receptors
Positron-Emission Tomography
Therapeutics
Placebos
Electrons
Aripiprazole

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Mechanism of new antipsychotic medications : Occupancy is not just antagonism. / Gründer, Gerhard; Carlsson, Arvid; Wong, Dean Foster.

In: Archives of General Psychiatry, Vol. 60, No. 10, 01.10.2003, p. 974-977.

Research output: Contribution to journalArticle

@article{9e2d19f260b64ab48ce6a7728d756221,
title = "Mechanism of new antipsychotic medications: Occupancy is not just antagonism",
abstract = "Antagonism of D2-like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60{\%} and 80{\%} (striatal) D2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80{\%} threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95{\%} of striatal D 2-like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is aripiprazole's weak partial agonism at D2-like dopamine receptors. This particular pharmacologic feature characterizes a new class of atypical antipsychotics that does not match the original concept of a therapeutic occupancy window for antagonist antipsychotics. When not involving pure antagonists, it implies a need to adjust the expected receptor occupancy (measured using positron emission tomography) for the therapeutic window.",
author = "Gerhard Gr{\"u}nder and Arvid Carlsson and Wong, {Dean Foster}",
year = "2003",
month = "10",
day = "1",
doi = "10.1001/archpsyc.60.10.974",
language = "English (US)",
volume = "60",
pages = "974--977",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Mechanism of new antipsychotic medications

T2 - Occupancy is not just antagonism

AU - Gründer, Gerhard

AU - Carlsson, Arvid

AU - Wong, Dean Foster

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Antagonism of D2-like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80% (striatal) D2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D 2-like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is aripiprazole's weak partial agonism at D2-like dopamine receptors. This particular pharmacologic feature characterizes a new class of atypical antipsychotics that does not match the original concept of a therapeutic occupancy window for antagonist antipsychotics. When not involving pure antagonists, it implies a need to adjust the expected receptor occupancy (measured using positron emission tomography) for the therapeutic window.

AB - Antagonism of D2-like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80% (striatal) D2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D 2-like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is aripiprazole's weak partial agonism at D2-like dopamine receptors. This particular pharmacologic feature characterizes a new class of atypical antipsychotics that does not match the original concept of a therapeutic occupancy window for antagonist antipsychotics. When not involving pure antagonists, it implies a need to adjust the expected receptor occupancy (measured using positron emission tomography) for the therapeutic window.

UR - http://www.scopus.com/inward/record.url?scp=10744232425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232425&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.60.10.974

DO - 10.1001/archpsyc.60.10.974

M3 - Article

C2 - 14557141

AN - SCOPUS:10744232425

VL - 60

SP - 974

EP - 977

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 10

ER -